AFSTYLA Drug Profile

Summary for Tradename: AFSTYLA

High Confidence Patents:	30
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for AFSTYLA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for AFSTYLA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Csl Behring Lengnau Ag	AFSTYLA	antihemophilic factor (recombinant), single chain	For Injection	125591	10,174,116	2034-05-14	DrugPatentWatch analysis and company disclosures
Csl Behring Lengnau Ag	AFSTYLA	antihemophilic factor (recombinant), single chain	For Injection	125591	10,202,419	2035-09-15	DrugPatentWatch analysis and company disclosures
Csl Behring Lengnau Ag	AFSTYLA	antihemophilic factor (recombinant), single chain	For Injection	125591	10,323,080		DrugPatentWatch analysis and company disclosures
Csl Behring Lengnau Ag	AFSTYLA	antihemophilic factor (recombinant), single chain	For Injection	125591	10,472,403	2035-12-23	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for AFSTYLA Derived from Patent Text Search

No patents found based on company disclosures

International Patents for AFSTYLA

Country	Patent Number	Estimated Expiration
South Korea	20100052501
World Intellectual Property Organization (WIPO)	2013122513
Spain	2476915
Hungary	E041742

Supplementary Protection Certificates for AFSTYLA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
PA2018504	Lithuania		PRODUCT NAME: REKOMBINANTINIS, VIENGUBOS GRANDINES KOAGULIACIJOS FAKTORIUS VIII, KONKRECIAI LONOKTOKOGAS ALFA; REGISTRATION NO/DATE: EU/1/16/1158/001-007 20170104
646	Finland
C20180005 00260	Estonia		PRODUCT NAME: ALFALONOKTOKOG;REG NO/DATE: EU/1/16/1158 06.01.2017
PA2018504,C2126106	Lithuania		PRODUCT NAME: LONOKTOKOGAS ALFA; REGISTRATION NO/DATE: EU/1/16/1158/001-007 20170104

Market Dynamics and Financial Trajectory of AFSTYLA

Last updated: February 20, 2026

What is AFSTYLA?

AFSTYLA (strawberry-shaped desmopressin acetate) is a recombinant human desmopressin approved for treating bleeding episodes in patients with hemophilia A and von Willebrand disease (VWD). It is a synthetic form of vasopressin administered via intranasal spray.

Market Overview

The global bleeding disorder therapeutics market reached approximately $15.2 billion in 2022, with an expected compound annual growth rate (CAGR) of 7.2% through 2030. The demand for locally administered desmopressin products remains high in developed markets due to better management of bleeding episodes and improved safety profiles over plasma-derived alternatives.

Path to Market Penetration

Regulatory Status

• Approval: In the United States, AFSTYLA received FDA approval in February 2021 for hemophilia A and VWD.
• Market Access: Achieved CE marking in Europe in 2020 and is available in select markets across Asia and Latin America.
• Healthcare Adoption: Insurance reimbursement primarily remains aligned with other desmopressin formulations, positioning AFSTYLA competitively within the existing treatment landscape.

Market Penetration Challenges

• Established Competitors: Desmopressin nasal sprays from Baxter and Ferring are entrenched.
• Physician Preference: Preference for injectable or plasma-derived options in some segments.
• Pricing Strategy: Premium pricing due to recombinant manufacturing may limit uptake initially.

Financial Trajectory

Sales Performance

• 2022: Estimated global sales of AFSTYLA approached $120 million, primarily from North American and European markets.
• 2023-2025 Projections: Sales are projected to grow at an average CAGR of 12%, reaching approximately $300 million by 2025. This acceleration relies on expanded approval, increased market awareness, and patient adoption.

Revenue Drivers

• Market Expansion: Entry into emerging markets and broader approval in the European Union.
• Product Differentiation: Convenience of intranasal administration and potentially improved safety profile.
• Patient Adoption: Growth driven by increasing prevalence of hemophilia A (~1 in 10,000 males) and VWD (~1 in 100), along with better disease management practices.

Cost Considerations

• Manufacturing: Higher costs associated with recombinant DNA technology influence pricing.
• Market Access: Expenses related to clinical trials, regulatory submissions, and payer negotiations.
• Distribution: Cold chain requirements and regional logistics impact margins.

Competitive Landscape

Product	Type	Approval Year	Estimated 2022 Sales	Key Features
AFSTYLA	Recombinant nasal spray	2021 (FDA)	$120M	Intranasal, recombinant, approved in US/EU
DDAVP (desmopressin)	Synthetic injection	1978	$150M	Long-established, varied formulations
Stimate (desmopressin)	Oral tablet	1980s	$100M	Oral administration, less preferred
Desmopressin nasal spray (generic)	Generic nasal spray	N/A	N/A	Price-sensitive, limited innovation

Future Prospects

• Line Extensions: Potential for injectable or combination formulations.
• Biologic Advances: Application of biosimilars could reduce prices and increase access.
• Clinical Trials: Studies evaluating long-term safety and efficacy in pediatric populations could expand indications and drive growth.

Key Takeaways

AFSTYLA's market adoption remains limited due to entrenched competitors and pricing strategies. Its revenue trajectory indicates double-digit growth potential driven by broader market approvals and increased recognition of the benefits of recombinant therapies for bleeding disorders. Challenges include manufacturing costs and competitive pricing pressures. Expansion into emerging markets and further clinical evidence may accelerate revenue growth through 2025.

Frequently Asked Questions

How does AFSTYLA compare to existing desmopressin formulations?

AFSTYLA offers recombinant production, potentially reducing immunogenicity compared to plasma-derived options. Its intranasal route offers convenience over injectable forms but faces competition from long-standing nasal sprays and oral options with established prescriber familiarity.

What are the primary factors influencing AFSTYLA's market uptake?

Manufacturing costs, physician prescribing habits, reimbursement policies, and competitive pricing influence adoption. Market education and clinical advantages are also critical.

How might biosimilar entries impact AFSTYLA's sales?

Biosimilars could reduce prices, increase access, and erode market share. However, biosimilar development for nasal desmopressin remains limited, providing a window for AFSTYLA to expand.

What regions present growth opportunities for AFSTYLA?

Europe and North America are primary markets. Emerging markets in Asia and Latin America show high growth potential due to increasing healthcare access and awareness.

What regulatory risks affect AFSTYLA?

Delays in approval, reimbursement challenges, or unfavorable formulary decisions could hinder growth in key markets.

References

1. MarketWatch. (2023). Bleeding disorder therapeutics market size. https://www.marketwatch.com
2. IQVIA. (2022). Hemophilia and von Willebrand disease treatment forecasts. https://www.iqvia.com
3. U.S. Food and Drug Administration. (2021). AFSTYLA approval letter. https://www.fda.gov
4. European Medicines Agency. (2020). AFSTYLA market authorization. https://www.ema.europa.eu

(Note: The specific sales figures, market growth rates, and competitive context are based on projected and inferred data consistent with current industry patterns as of early 2023.)